Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,463 total articles

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

ArriVent BioPharma announced that its Phase 3 FURVENT clinical trial evaluating firmonertinib monotherapy in first-line treatment of locally advanced or metastatic non-squamous NSCLC patients with EGFR exon 20 insertion mutations did not meet its primary endpoint of progression-free survival by blinded independent central review. Although secondary…

SailPoint Report Finds 79% of Enterprises Run AI Agents in Production, Yet Only 2% Have Deployed Purpose-built Security

SailPoint Report Finds 79% of Enterprises Run AI Agents in Production, Yet Only 2% Have Deployed Purpose-built Security

SailPoint's 2026 Horizons of Identity Security report reveals that while 79% of enterprises have deployed AI agents in production, only 2% have purpose-built identity security controls for them, exposing significant operational and compliance risks. The report emphasizes the urgent need to advance from foundational identity security practices to au…

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Pelthos Therapeutics announced new formulary agreements that increase access to ZELSUVMI (berdazimer) topical gel, a novel treatment for molluscum contagiosum, to a total of 127 million commercially covered lives plus strong Medicaid coverage. This includes a major Pharmacy Benefit Manager covering 24 million lives without prior authorization and a…

Pasqal Reaffirms its Commitment to the EU’s Quantum Ambitions as It Leads Q-PLANET for Neutral-Atom Technologies

Pasqal Reaffirms its Commitment to the EU’s Quantum Ambitions as It Leads Q-PLANET for Neutral-Atom Technologies

Pasqal has taken a leading role in the Q-PLANET consortium, which is funded with €50 million by the EU Chips Joint Undertaking and national authorities. The initiative aims to develop industrial-grade chip components for neutral-atom quantum computing, sensing, and communication over the next three years. This effort supports the European Union's s…

NANO Nuclear Energy Appoints Former Y-12 Leader and Nuclear Fuel Cycle Expert Jennifer Charlton, Ph.D., as Vice President of Fuel Technology to Accelerate Vertical Integration Strategy

NANO Nuclear Energy Appoints Former Y-12 Leader and Nuclear Fuel Cycle Expert Jennifer Charlton, Ph.D., as Vice President of Fuel Technology to Accelerate Vertical Integration Strategy

NANO Nuclear Energy Inc. announced the hiring of Jennifer Charlton, Ph.D., a seasoned nuclear fuel cycle expert and former Y-12 National Security Complex leader, as Vice President of Fuel Technology. This strategic appointment aims to accelerate NANO Nuclear's vertical integration across the nuclear fuel cycle, supporting its advanced micro modular…

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

vTv Therapeutics announced a virtual key opinion leader event scheduled for October 20, 2026, featuring diabetes experts and patient advocates to discuss challenges in type 1 diabetes, hypoglycemia risk, and the company's phase 3 trial of cadisegliatin, an oral glucokinase activator. The event aims to provide insights into the ongoing CATT1 trial w…

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

YD Bio Limited (Nasdaq: YDES) and EG BioMed have introduced an AI-based online cancer risk assessment tool that evaluates individual self-reported health data to generate personalized risk reports for ten major cancer types. This tool integrates with their oncology services and aims to empower users with insights for informed healthcare discussions…

Rezolve Ai Showcases Agentic Commerce Platform at Nasdaq Investor Day and Publishes U.S. AI Visibility Study

Rezolve Ai Showcases Agentic Commerce Platform at Nasdaq Investor Day and Publishes U.S. AI Visibility Study

Rezolve Ai, listed on NASDAQ as RZLV, hosted its Investor Day at the Nasdaq MarketSite showcasing its full agentic commerce platform with live demonstrations and revealing key findings from its US AI Visibility Study 2026. The study highlights a significant gap in AI agent engagement among America's largest retailers, underscoring the necessity for…

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

Entera Bio Ltd., a clinical-stage biopharmaceutical company developing oral peptide therapies, has appointed Laura Hamill, an experienced global commercial leader from Gilead Sciences and Amgen, to its Board of Directors effective December 1, 2026. This strategic move aims to leverage her expertise to support Entera’s late-stage clinical developmen…

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

LB Pharmaceuticals Inc (Nasdaq: LBRX) announced an in-person and virtual R&D Day on October 27, 2026, focusing on its lead investigational drug LB-102, a novel antipsychotic in Phase 3 development for schizophrenia. The event will feature presentations from key company executives and prominent psychiatrist Dr. Roger S. McIntyre, providing scientifi…

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

Akebia Therapeutics announced multiple presentations at the ASN Kidney Week 2026, including a late-breaking presentation of the VOICE trial assessing vadadustat for anemia in hemodialysis patients, as well as posters on their rare kidney disease pipeline and clinical and economic outcomes for their drug Vafseo (vadadustat). These updates underscore…

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Madrigal Pharmaceuticals announced publication of a secondary analysis from their Phase 3 MAESTRO-NASH trial demonstrating that Rezdiffra (resmetirom) effectively improves liver histology, reduces fibrosis, and lowers liver fat and biomarkers across multiple genetic variants associated with metabolic dysfunction-associated steatohepatitis (MASH). T…

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Collegium Pharmaceutical, a Nasdaq-listed biopharmaceutical firm, has launched Start Talking ADHD, an online resource with practical guides to assist patients and families managing ADHD in healthcare, education, and daily life contexts. The initiative accompanies Collegium's recent expansion of its ADHD medication portfolio, underscoring the compan…

Global Ship Lease Announces Exercise of Newbuild Options

Global Ship Lease Announces Exercise of Newbuild Options

Global Ship Lease, a NYSE-listed containership owner and lessor, announced it has exercised options to build two additional state-of-the-art, mid-size, ultra-high-reefer, wide-beam containerships for approximately $163 million, with delivery scheduled in Q4 2029. This decision increases its newbuilding orderbook to 17 ships, aligning with its strat…

Turning Savings into Security: Canadians Feel on Track for Retirement, But Worry About What Comes Next

Turning Savings into Security: Canadians Feel on Track for Retirement, But Worry About What Comes Next

BlackRock's inaugural Canada Read on Retirement report reveals that while Canadian workers participating in retirement plans are generally confident in their savings progress, many remain uncertain about their long-term retirement security. Key concerns include worries about outliving savings, challenges posed by inflation and market volatility, an…

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

Galectin Therapeutics announced its participation in the AASLD Liver Meeting 2026 with three presentations highlighting positive trial data of belapectin for treating MASH cirrhosis and portal hypertension. The company also submitted the Phase 3 registrational protocol for belapectin to the FDA, marking a critical step toward developing the first t…

BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder

BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder

BullFrog AI disclosed progress in its commercial drug discovery program targeting major depressive disorder for a top 5 global pharmaceutical company. Utilizing its proprietary AI platform, the company successfully identified and prioritized novel neuropsychiatric therapeutic targets, validating its technology and reinforcing its commercial strateg…